BioSpace News Archive

DermTech, Inc., a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced the additions of Dr. Klaus Busam, Dr. Joslyn Kirby and Dr. Justin Ko to its Scientific Advisory Board.

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced initial data from an ongoing Phase 1b study evaluating ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel, in advanced solid tumors.

Labcorp (NYSE: LH), a leading global life sciences company, today announced the introduction of its combined Labcorp oncology platform at the virtual 2021 American Society of Clinical Oncology (ASCO®) Annual Meeting held June 4-8.

QBiotics Group Limited (QBiotics), a life sciences company developing novel small molecule anticancer and wound healing pharmaceuticals, is pleased to announce that it has dosed the first patient in the Phase Ib/IIa clinical trial of the company’s lead oncology molecule, tigilanol tiglate

Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the 2021 LD Micro Invitational XI.

Ionis Pharmaceuticals, Inc. announced changes to its board of directors. Joseph Loscalzo, M.D., Ph.D., has been appointed chairman of the board and Allene M. Diaz has been appointed to the board.

MedX Health Corp. announces that, subject to TSX-V Acceptance, it has entered into an agreement to redeem an existing $500,000 secured loan by way of a non-brokered Private Placement of 10 Convertible Debenture Loan Notes, each with a face value of $50,000 to the same accredited investor.

Arcline Investment Management (“Arcline”), a growth-oriented private equity firm, today announced that it has acquired a controlling stake in Resolution Medical, LLC

Canada’s approach to vaccination has enabled individuals in Canada to protect themselves, their families and communities against severe COVID-19 outcomes and reduce the risk of transmission of the virus.

Cognoa, a pediatric behavioral health company developing diagnostic and therapeutic solutions for children living with behavioral health conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted the company’s De Novo classification request for its autism diagnosis aid